Cipla USA, Inc.: Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled
Recall reason: Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.. Recalled by Cipla USA, Inc.. Distribution: Nationwide in the USA. Classification (Class II — potential health risk). Affected lots/NDC/dates: Lot, expiry: 4401699IR1, Exp. 5/31/2026; 4401699IR2, Exp. 5/31/2026; 4401700IR1, Exp. 5/31/2026; 4401701IR1, Exp. 5/. Return the recalled medication to the pharmacy where you purchased it for a full refund of the purchase price.
📬 Get email alerts for new Product Recalls & Refunds
Free — we'll email you when new matching opportunities appear. No spam, unsubscribe anytime.
New here? Here's how Reward Opportunity works:
🔔 More Product Recalls & Refunds
Product recalls offering refunds, replacements, or repairs to consumers who purchased the item.
Browse all product recalls & refunds →Not just this one — find everything you qualify for
Our AI scans 8,000+ bounties, settlements, grants, recalls, and paid studies against your profile to rank what you can actually claim.
Get My Free Match Report